AstraZeneca completes acquisition of Fusion Pharmaceuticals

Fusion Pharmaceuticals (FUSN) announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca (AZN) by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. As a result of the Arrangement, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations continuing in Canada and the US. Fusion shares will be delisted from the Nasdaq Stock Market and deregistered under the U.S. Securities Exchange Act of 1934. Fusion has submitted an application to cease to be a reporting issuer under applicable Canadian securities laws and to otherwise terminate Fusion’s Canadian public reporting requirements.